Indication
COVID-19 Pneumonia
44 clinical trials
47 products
4 drugs
Clinical trial
A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/IIIStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
BDB-001Product
Mesenchymal Stem CellsClinical trial
Double Blind, Placebo-controlled, Phase I/II Clinical Trial to Evaluate Safety and Efficacy of Allogeneic Mesenchymal Stem/Stromal Cells MSV-allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (MSV-COVID)Status: Completed, Estimated PCD: 2021-10-28
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and Dose-range-finding to Evaluate the Efficacy and Safety in Treatments for COVID-19 in Hospitalized AdultsStatus: Terminated, Estimated PCD: 2023-02-03
Product
TF0023Clinical trial
Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung DiseaseStatus: Completed, Estimated PCD: 2021-12-31
Product
MethylprednisoloneClinical trial
A Phase 1 Study of DVX201, an Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19Status: Completed, Estimated PCD: 2022-06-07
Product
DVX201Product
PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 PneumoniaStatus: Completed, Estimated PCD: 2020-08-18
Product
TocilizumabClinical trial
Exploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 PneumoniaStatus: Completed, Estimated PCD: 2021-02-28
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-009A Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 PneumoniaStatus: Withdrawn, Estimated PCD: 2023-05-01
Product
EG-009AProduct
DexamethasoneProduct
F-652Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of F-652 in Subjects With COVID-19 PneumoniaStatus: Withdrawn, Estimated PCD: 2022-04-08
Product
NestaCell®Clinical trial
A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus: Recruiting, Estimated PCD: 2023-12-01
Product
Recombinant COVID-19 VaccineProduct
Standard of CareProduct
Inactivated COVID-19 vaccineClinical trial
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2Status: Completed, Estimated PCD: 2021-10-20
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multi- Centre, Adaptive Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For SARS-CoV-2 InfectionStatus: Recruiting, Estimated PCD: 2024-07-01
Product
RamatrobanProduct
Bacillus subtilisClinical trial
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal FunctionStatus: Recruiting, Estimated PCD: 2024-02-28
Clinical trial
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Product
COVID-19 vaccineProduct
GST-HG171Product
SARS-CoV-2 VaccineClinical trial
Immunogenicity Non-inferiority Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 Years Old vs Healthy Population Aged 18 Years Old and AboveStatus: Completed, Estimated PCD: 2022-03-31
Product
BromAcClinical trial
Safety of Nebulised Delivery of BromAc® (Bromelain & Acetylcysteine) in Healthy Volunteers: a Potential Treatment for Severe COVID-19Status: Completed, Estimated PCD: 2022-08-14
Clinical trial
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver FunctionStatus: Completed, Estimated PCD: 2023-02-06
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of GST-HG171/Ritonavir in Patients With Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2023-05-31
Product
NuSepinClinical trial
A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID-19 Pneumonia PatientsStatus: Recruiting, Estimated PCD: 2024-11-30
Product
GST-HG171/RitonavirProduct
STI-1558Clinical trial
A Study to Evaluate the Relative Bioavailability of Different Strengths of STI-1558 Capsules and the Effect of Strong CYP3A4 Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics of STI-1558 in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-03-15
Product
RifampinProduct
ItraconazoleClinical trial
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster DoseStatus: Completed, Estimated PCD: 2023-03-15
Product
Pfizer COVID-19 mRNA vaccineClinical trial
Cromolyn Sodium for Treatment of COVID-19 PneumoniaStatus: Recruiting, Estimated PCD: 2024-06-01
Product
Cromolyn SodiumClinical trial
SECOVID: A Multi-center, Randomized, Dose-ranging Parallel-group Trial Assessing the Efficacy of Sirolimus in Hospitalized Patients With COVID-19 Pneumonia for the Prevention of Post-COVID FibrosisStatus: Recruiting, Estimated PCD: 2024-06-01
Product
SirolimusClinical trial
Safety and Tolerability of Allogeneic Umbilical Cord Derived Mesenchymal Stromal Cells (UC-MSCs) to Limit COVID Associated ComplicatioNs: An Open Label, Phase 1 Study in Hospitalized Patients (SAMPSON-1)Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19Status: Recruiting, Estimated PCD: 2024-05-31
Product
BailingClinical trial
A Pilot Study to Assess the Safety, Tolerability and Efficacy of Selectin Inhibitor Uproleselan (GMI-1271) in Patients With COVID-19 PneumoniaStatus: Terminated, Estimated PCD: 2022-03-09
Product
UproleselanClinical trial
Macrophage Regulation of Ozone-Induced Lung InflammationStatus: Recruiting, Estimated PCD: 2028-05-01
Product
OzoneClinical trial
The Efficacy and Safety of Bevacizumab in Patients With Severe Covid-19: a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2023-11-30
Drug
AtezolizumabClinical trial
The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes MellitusStatus: Withdrawn, Estimated PCD: 2021-12-01
Drug
JAKiProduct
RemdesivirClinical trial
A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 PatientsStatus: Terminated, Estimated PCD: 2022-03-22
Drug
VarlilumabProduct
DipyridamoleClinical trial
Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19Status: Recruiting, Estimated PCD: 2024-04-30
Product
Lianhua QingwenClinical trial
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 PneumoniaStatus: Completed, Estimated PCD: 2021-10-20
Drug
TocilizumabClinical trial
Traditional Chinese Medicine or Low-dose Dexamethasone in Symptomatic Patients With Post-COVID-19 Parenchymal Lung Abnormalities: a Randomized Controlled Trial Three Arm, Parallel Group, Single Blind, Randomized Controlled Trial.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 PneumoniaStatus: Active (not recruiting), Estimated PCD: 2023-12-19
Clinical trial
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)Status: Completed, Estimated PCD: 2022-06-21
Product
MolgramostimClinical trial
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Lung Cancer or Indeterminate Pulmonary Nodule--A Real World StudyStatus: Withdrawn, Estimated PCD: 2021-08-31
Product
Vaccine against SARS-CoV-2Clinical trial
Evaluation of the Efficacy and Safety of Nano-S1 in Adult Patients Infected With SARS-Cov-2: "COVID Nano-S1Status: Completed, Estimated PCD: 2022-01-01
Product
NANOS1Clinical trial
Clinical Study on the Safety and Efficacy of Mesenchymal Stem Cell Exosomes in the Treatment of Coronavirus Infection.Status: Recruiting, Estimated PCD: 2024-01-23
Clinical trial
Usefulness of DORNASE (Pulmozyme®) in Patients With COVID-19 Respiratory Insufficiency on High-Flow Oxygen TherapyStatus: Terminated, Estimated PCD: 2023-02-22
Product
Dornase AlfaClinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pirfenidone in Adult Hospitalized Patients With COVID-19.Status: Active (not recruiting), Estimated PCD: 2023-03-02
Product
PirfenidoneClinical trial
ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)Status: Recruiting, Estimated PCD: 2025-07-01
Product
Inhaled placeboClinical trial
Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)Status: Active (not recruiting), Estimated PCD: 2022-02-25
Product
Mesenchymal stromal cellsClinical trial
A Clinical Trial to Evaluate the Immunogenicity Bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in Healthy Population Aged 18-59 YearsStatus: Completed, Estimated PCD: 2023-03-11
Product
Recombinant COVID-19 vaccineProduct
COVID-19 Rice Drug